In Week of Mar 28, 2026, Emcure Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +27.3% relative strength. Fundamentals: Strong. On a 11-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: 57% revenue from international markets growing 24.5% YoY with Europe +29.6%, RoW +30.7%, Canada +12.8%
Impact: +₹500 Cr revenue
“International business now constitutes 57% revenue mix; Europe benefited from Manx acquisition and Amphotericin B launches”
What: Domestic cardio-diabetic therapies and Poviztra semaglutide driving 15.4% domestic growth
Impact: +₹200 Cr revenue
“Domestic business continues to outpace the Indian Pharmaceutical Market (IPM) growth rate”
What: Novo Nordisk partnership for weight management amid patent expiry dynamics
Impact: +₹100 Cr revenue
“Domestic weight management entry via Novo Nordisk partnership positions Emcure for obesity segment growth”
Earnings deceleration risks from management commentary
Trigger: New product launches with lower margins
Impact: -80 bps margin impact
Management view: Gross margins for the quarter stood at 59.3% versus 60.1% in 3Q of 26. The decline was largely due to the in... (incomplete quote)
Monitor: Gross margin trend
Trigger: Additional regulatory compliance costs
Impact: -160 bps margin impact
Management view: Adjusted PAT excluding labor code grew by more than 65%
Monitor: One-time expenses
Key quotes from recent conference calls
“All international businesses delivered strong growth along all verticals which helped us to deliver... — Management”
“EBITDA margin expanded by 110 basis points to 19.5% despite investment in new initiatives and impact of sonopi diabetes in licensing portfolio — Management”
“Domestic business continues to outpace the Indian Pharmaceutical Market (IPM) growth rate — Management”
“We remain on track to grow in mid-teens for the year — Management”
Forward-looking targets from management for FY26
Revenue Growth Target
15%
Key Milestones
• Mid-teens revenue growth for FY26
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +20% | +10% | Stable |
| PAT (Net Profit) | +48% | +0% | Stable |
| OPM | 21.0% | +300 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Emcure Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
Emcure Pharmaceuticals Ltd's profit is growing with an stable trend.
Emcure Pharmaceuticals Ltd's revenue growth trend is stable.
Emcure Pharmaceuticals Ltd's operating margin is expanding.
Emcure Pharmaceuticals Ltd's long-term compounding rates
Emcure Pharmaceuticals Ltd's earnings growth is stable with mixed signals on a sequential basis.
Emcure Pharmaceuticals Ltd's trailing twelve month (TTM) performance
Emcure Pharmaceuticals Ltd appears undervalued based on our fair value analysis.
Emcure Pharmaceuticals Ltd's current PE ratio is 34.6x.
Emcure Pharmaceuticals Ltd's current PE is 34.6x.
Emcure Pharmaceuticals Ltd's price-to-book ratio is 6.6x.
Emcure Pharmaceuticals Ltd is rated Strong with a fundamental score of 64.99/100. This score is calculated from objective financial metrics
Emcure Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Emcure Pharmaceuticals Ltd's return ratios over recent years
Emcure Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
Emcure Pharmaceuticals Ltd's current dividend yield is 0.18%.
Emcure Pharmaceuticals Ltd's shareholding pattern (Dec 2025)
Emcure Pharmaceuticals Ltd's promoter holding has decreased recently.
Emcure Pharmaceuticals Ltd has been outperforming Nifty 500 for 11 consecutive weeks, indicating consistent outperformance.
Emcure Pharmaceuticals Ltd is an established outperformer with 11 weeks of consecutive Nifty 500 outperformance.
Emcure Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis
Emcure Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q3 FY26, Emcure Pharmaceuticals Ltd's management highlighted
Emcure Pharmaceuticals Ltd's management has provided the following forward guidance for FY26
Based on quantitative research signals, here is why Emcure Pharmaceuticals Ltd may be worth studying
Emcure Pharmaceuticals Ltd investment thesis summary:
Emcure Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
